Lancashire and South Cumbria
Formulary
Formulary
4 Central nervous system
04-05-01 Anti-obesity drugs acting on the gastro-intestinal tract
| Liraglutide Saxenda® |
|
Formulary
|
6mg/ml solution for injection 3ml pre-filled pens liraglutide is recommended as an option in overweight and obesity as long as it is prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service
|
 MHRA: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued MHRA: Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products NICE TA664: Liraglutide for managing overweight and obesity |
|
for NICE TA749 Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal)| Orlistat |
|
Formulary
|
| Capsules 120mg |
|
MHRA: Orlistat: theoretical interaction with antiretroviral HIV medicines |
|
| Semaglutide Wegovy® |
|
Formulary
|
Solution for injection in pre filled pen 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg Only available via referral to a Tier 3 Weight Management Service.
|
|
MHRA: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued NICE TA875: Semaglutide for managing overweight and obesity |
|
|
| Tirzepatide Mounjaro® |
|
Formulary
|
Pre-filled pens, solution for injection. Obesity. |
|
LSCMMG: Tirzepatide |
|
Links
- LSCMMG: Tirzepatide
- MHRA Drug Safety Update Aug 2019: Naltrexone/bupropion (Mysimba): risk of adverse reactions that could affect ability to drive
- MHRA Drug Safety Update Jue 2019: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
- MHRA: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
- MHRA: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
MHRA: Interaction with HIV medicines- MHRA: Orlistat: theoretical interaction with antiretroviral HIV medicines
- MHRA: Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products
- NICE CG189: Obesity: identification, assessment and management
- NICE TA664: Liraglutide for managing overweight and obesity
- NICE TA664: Liraglutide for managing overweight and obesity
- NICE TA749: Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal)
- NICE TA875 Semaglutide for managing overweight and obesity
- NICE TA875: Semaglutide for managing overweight and obesity
- NICETA910:Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal)